1.
Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists
by Askling, Johan
Annals of the rheumatic diseases, 2007, Vol.66 (10), p.1339-1344
2.
Ankylosing spondylitis
by Braun, Jürgen, Prof
The Lancet (British edition), 2007, Vol.369 (9570), p.1379-1390
3.
Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies
by Avina-Zubieta, Juan Antonio
Annals of the rheumatic diseases, 2012, Vol.71 (9), p.1524-1529
4.
High anti-collagen type-II antibody levels and induction of proinflammatory cytokines by anti-collagen antibody-containing immune complexes in vitro characterise a distinct rheumat...
by Mullazehi, Mohammed
Annals of the rheumatic diseases, 2007, Vol.66 (4), p.537-541
5.
Mechanism of Action of Colchicine in the Treatment of Gout
by Dalbeth, Nicola, MD
Clinical therapeutics, 2014, Vol.36 (10), p.1465-1479
6.
2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis
by Braun, J
Annals of the Rheumatic Diseases, 2011, Vol.70 (6), p.896-904
7.
Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial
by McInnes, Iain B, Dr
The Lancet (British edition), 2013, Vol.382 (9894), p.780-789
8.
Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial
by Baeten, Dominique, MD
The Lancet (British edition), 2013, Vol.382 (9906), p.1705-1713
9.
Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study
by Keystone, E C
Annals of the rheumatic diseases, 2009, Vol.68 (6), p.789-796
10.
Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores
by Machado, Pedro
Annals of the rheumatic diseases, 2011, Vol.70 (1), p.47-53
12.
2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative
by Aletaha, Daniel
Annals of the rheumatic diseases, 2010, Vol.69 (9), p.1580-1588
13.
A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management...
by Ash, Zoe
Annals of the Rheumatic Diseases, 2012, Vol.71 (3), p.319-326
14.
EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases
by van Assen, S
Annals of the Rheumatic Diseases, 2011, Vol.70 (3), p.414-422
15.
Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review
by Jamnitski, Anna
Annals of the rheumatic diseases, 2013, Vol.72 (2), p.211-216
16.
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
by Smolen, Josef S
Annals of the Rheumatic Diseases, 2010, Vol.69 (6), p.964-975
17.
European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies
by Gossec, L
Annals of the Rheumatic Diseases, 2012, Vol.71 (1), p.4-12
18.
Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial
by Gabay, Cem, MD
The Lancet (British edition), 2013, Vol.381 (9877), p.1541-1550
19.
2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative
by Dasgupta, Bhaskar
Annals of the rheumatic diseases, 2012, Vol.71 (4), p.484-88
20.
Patient and provider barriers to effective management of gout in general practice: a qualitative study
by Spencer, Karen
Annals of the rheumatic diseases, 2012, Vol.71 (9), p.1490-1495
